OLAYEMI OLAJUYIGBE: Open Payments
NPI 1073170205 · ELKRIDGE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$781 in 33 payments from 9 companies in 2025. Trend: 2023 $710 · 2024 $632 · 2025 $781
Food & beverage: $781
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 9 | $165 |
| TMS NeuroHealth Centers Inc. | 2 | $149 |
| Lundbeck LLC | 8 | $149 |
| ABBVIE INC. | 4 | $85 |
| Neurocrine BioSciences, Inc. | 3 | $74 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| E.R. Squibb & Sons, L.L.C. | 2 | $45 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
Products named: ARISTADA, TMS NeuroHealth Centers Inc., VRAYLAR, REXULTI, INGREZZA, ABILIFY ASIMTUFII, ABILIFY MAINTENA, CAPLYTA.
Industry payments across MD — which companies pay providers there.
